TITLE

CD4 Lymphocyte Percentage Predicts Disease Progression in HIV-Infected Patients Initiating Highly Active Antiretroviral Therapy with CD4 Lymphocyte Counts >350 Lymphocytes/mm3

AUTHOR(S)
Hulqan, Todd; Raffanti, Stephen; Kheshti, Asqhar; Blackwell, Robert B.; Rebeiro, Peter F.; Barkanic, Gema; Ritz, Brandon; Sterling, Timothy R.
PUB. DATE
September 2005
SOURCE
Journal of Infectious Diseases;9/15/2005, Vol. 192 Issue 6, p950
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The optimal timing of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV)-infected patients with ⩾200 absolute CD4 lymphocytes/mm³ is unknown. CD4 lymphocyte percentage could add prognostic information. Methods. Persons who initiated HAART between 1 January 1998 and 1 January 2003, received ⩾30 days of therapy, and had baseline CD4 lymphocyte data available were included in the study. The log-rank test for time to event and Cox proportional hazards models were used to determine predictors of a new acquired immunodeficiency syndrome–defining illness or death. Results. A total of 788 patients met the inclusion criteria. At baseline, subjects had a median of 225 CD4 lymphocytes/mm³ and 17% CD4 lymphocytes. Subjects with <17% CD4 lymphocytes had earlier disease progression, compared with subjects with ⩾17%, both in the entire cohort (P < .0001) and of those subjects with >350 absolute CD4 lymphocytes/mm³ at baseline (P = .03). CD4 lymphocyte percentage <% was the strongest predictor of disease progression among subjects in this latter group (hazard ratio, 3.57; P = .045). Conclusions. In this cohort, CD4 lymphocyte percentage predicted disease progression in HIV-infected subjects who initiated therapy with >350 CD4 lymphocytes/mm³. This information may help identify persons who will derive the greatest benefit from initiation of HAART.
ACCESSION #
17988361

 

Related Articles

  • DIALYZABLE LEUKOCYTE EXTRACT (DLE) INHIBITS HIV-1 IN VITRO REPLICATION AS EARLY AS 24 HOURS OF INCUBATION BEFORE VIRUS CHALLENGE IN MT-4 CELLS. C., Fernández-Ortega; M., Ojeda; A., Giselle; Y., Ramos; L., Navea; L., Rodríguez; D., Casillas; L., Lovaina; E., Noa; I, Ruibal; Dubed, M. // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    The HIV pandemic has posed a challenge to the biomedical-research. HIV infection is characterized by the depletion of the CD4+ helper/inducer subset of T-lymphocytes, leading to severe immunosuppression, constitutional symptoms, neurological disease, and opportunistic infections and neoplasm....

  • Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. Kovacs, Joseph A.; Lempicki, Richard A.; Sidorov, Igor A.; Adelsberger, Joseph W.; Sereti, Irini; Sachau, William; Kelly, Grace; Metcalf, Julia A.; Davey, Richard T.; Falloon, Judith; Polis, Michael A.; Tavel, Jorge; Stevens, Randy; Lambert, Laurie; Hosack, Douglas A.; Bosche, Marjorie; Issaq, Haleem J.; Fox, Stephen D.; Leitman, Susan; Baseler, Michael W. // Journal of Clinical Investigation;Aug2005, Vol. 115 Issue 8, p2139 

    HIV infection leads to decreases in the number of CD4 T lymphocytes and an increased risk for opportunistic infections and neoplasms. The administration of intermittent cycles of IL-2 to HIV-infected patients can lead to profound increases (often greater than 100%) in CD4 cell number and...

  • Prioritizing CD4 Count Monitoring in Response to ART in Resource-Constrained Settings: A Retrospective Application of Prediction-Based Classification. Azzoni, Livio; Foulkes, Andrea S.; Yan Liu; Xiaohong Li; Johnson, Margaret; Smith, Collette; Kamarulzaman, Adeebabte; Montaner, Julio; Mounzer, Karam; Saag, Michael; Cahn, Pedro; Cesar, Carina; Krolewiecki, Alejandro; Sanne, Ian; Montaner, Luis J. // PLoS Medicine;Apr2012, Vol. 9 Issue 4, p1 

    Background: Global programs of anti-HIV treatment depend on sustained laboratory capacity to assess treatment initiation thresholds and treatment response over time. Currently, there is no valid alternative to CD4 count testing for monitoring immunologic responses to treatment, but laboratory...

  • Predictions of CD4 lymphocytes' count in HIV patients from complete blood count. Rodríguez, Javier O.; Prieto, Signed E.; Correa, Catalina; Pérez, Carlos E.; Mora, Jessica T.; Bravo, Juan; Soracipa, Yolanda; Álvarez, Luisa F. // BMC Medical Physics;2013, Vol. 13 Issue 1, p1 

    Background: HIV diagnosis, prognostic and treatment requires T CD4 lymphocytes' number from flow cytometry, an expensive technique often not available to people in developing countries. The aim of this work is to apply a previous developed methodology that predicts T CD4 lymphocytes' value based...

  • Causes of Infection and CD4+ Counts in Patients with HIV/AIDS. Emami Naeini, Alireza; Hemmasian Ettefagh, Helia; Shirani, Kiana; Mirzadeh, Farnoush; Bagheri, Ahmad // Journal of Isfahan Medical School;9/3/2012, Vol. 30 Issue 195, p1 

    Background: Infection with human immunodeficiency virus (HIV) causes progressive dysfunction of cell-mediated immune system. HIV-related immunosuppression significantly increases the risk for acquiring opportunistic infections due to bacteria, viruses, fungi, parasites, and protozoa. These...

  • Longitudinal progression of Neuropsychological deficits and immune suppression in a cohort of Asymptomatic HIV Seropositive subjects:. Gopukumar, K.; Rao, S. L.; Satishchandra, P.; Desai, A.; Ravi, V.; SubbaKrishna, D. K.; Mariyamma; Rao, B. S.; Satish, K. S.; Kumar, M. // Annals of Indian Academy of Neurology;2007 Supplement 2, Vol. 10, p47 

    Background: Asymptomatic HIV infection is associated with impaired cognitive functioning in Clade B. infection. The nature of cognitive change over time has not been studied in asymptomatic clade C infection. Objectives: The present study evaluated longitudinal progression in neuropsychological...

  • Increased Risk for Severe Malaria in HIV-1--infected Adults, Zambia. Chalwe, Victor; Van geertruyden, Jean-Pierre; Mukwamataba, Doreen; Menten, Joris; Kamalamba, John; Mulenga, Modest; D'Alessandro, Umberto // Emerging Infectious Diseases;May2009, Vol. 15 Issue 5, p749 

    To determine whether HIV-1 infection and HIV-1-related immunosuppression were risk factors for severe malaria in adults with some immunity to malaria, we conducted a case--control study in Luanshya, Zambia, during December 2005-March 2007. For each case-patient with severe malaria, we selected 2...

  • Immunologic Profile of Human Immunodeficiency Virus-Infected Patients during Viral Remission and Relapse on Antiretroviral Therapy. Wellons, Melissa F.; Gooding, Maria E.; Thomasch, James R.; Bartlett, John A.; Ottinger, Janet S.; Weinhold, Kent J.; Gryszowka, Victoria; Sanders, Linda L.; Edwards, Lloyd J. // Journal of Infectious Diseases;5/15/2001, Vol. 183 Issue 10, p1522 

    Compares HIV patients with stable CD4... lymphocytes during viral relapse while receiving treatment with patients who had sustained virus suppression. Antiretroviral treatment and virologic histories; Extended flow cytometry; Multivariable regression analyses.

  • Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors - CRF01_AE and Subtype B. Lau, Katherine A.; Wang, Bin; Miranda-Saksena, Monica; Boadle, Ross; Kamarulzaman, Adeeba; Ng, Kee-Peng; Saksena, Nitin K. // Current HIV Research;Apr2010, Vol. 8 Issue 3, p259 

    In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics